
Keywords: COPD; Budesonide; Formoterol fumarate dihydrate; Glycopyrronium; Co-suspension delivery technology; Pharmacokinetic; AE; adverse event; AUC0-â; area under the plasma concentration-time curve from time 0 to infinity; AUC0-12; area under the plasma